Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Pieris Pharmaceuticals Inc
PIRS | US
16.80
USD-0.12
-0.70%
PIRS | US
About Pieris Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
16.80
Open
16.91
High
16.91
Low
16.66
Pieris Pharmaceuticals Inc. a clinical-stage biopharmaceutical company discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate elarekibep used for the treatment of asthma; and PRS-220 an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier AstraZeneca AB and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals Inc. was incorporated in 2000 and is headquartered in Boston Massachusetts.
View LessPIRS | US
Risk
23.9
Sharpe
-0.25
Luna's Score
42/100
Recommendation
Sell
Luna says (PIRS | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
20.1%1 month
23.9%3 months
183.3%6 months
137.8%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.20
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
-1.47
Ent. to rev.
1.76
PEG
-
Other Fundamentals
EBITDA
-11.34M
MarketCap
22.18M
MarketCap(USD)
22.18M
Div. yield
-
Op. margin
-56.90
Erngs. growth
-
Rev. growth
-97.30
Ret. on equity
-80.46
Short ratio
2.59
Short perc.
2.58
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.93
Range1M
1.20
Range3M
11.38
Volumes: Market Activity
Rel. volume
0.41
Price X volume
38.88K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.47 | 0.53 | Cheaper |
| Ent. to Revenue | 1.76 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.20 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 183.32 | 72.80 | Riskier |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 22.18M | 3.66B | Emerging |
